No Data
No Data
Voydeya Approved in Canada as Add-on Therapy to Ravulizumab or Eculizumab for Adults With the Rare Disease PNH Who Have Residual Hemolytic Anemia Due to Extravascular Hemolysis
J.P. Morgan Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating
Morgan Stanley Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating, Raises Target Price to $188.2
Guggenheim Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating, Raises Target Price to $177.65
Three UK Exchange Stocks Estimated To Be Valued Up To 39.2% Below Intrinsic Worth
J.P. Morgan Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating, Announces Target Price $167.75
No Data